Acute HPA axis response to naltrexone differs in female vs. male smokers

Psychoneuroendocrinology

Volumn 35, Issue 4, 2010, Pages 596-606

  Roche, Daniel J O ^a   Childs, Emma ^a   Epstein, Alyssa M ^b   King, Andrea C ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACTH; Cigarette smoking; Cortisol; Hypothalamic pituitary adrenal (HPA) axis; Naltrexone; Sex differences

Indexed keywords

CORTICOTROPIN; ESTROGEN; HYDROCORTISONE; NALTREXONE; NICOTINE; PLACEBO;

ARTICLE; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; DOUBLE BLIND PROCEDURE; FEMALE; HORMONE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MENSTRUAL CYCLE; NEUROENDOCRINE SYSTEM; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; SEX DIFFERENCE; SMOKING CESSATION; STRESS;

ADRENOCORTICOTROPIC HORMONE; ADULT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PITUITARY-ADRENAL SYSTEM; PLACEBOS; SEX CHARACTERISTICS; SMOKING; TIME FACTORS; YOUNG ADULT;

EID: 77950690338     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2009.09.016     Document Type: Article

References (113)

1. Aceto M.D., Scates S.M., Ji Z., Bowman E.R. Nicotine's opioid and anti-opioid interactions: proposed role in smoking behavior. Eur. J. Pharmacol. 1993, 248:333-335.
2. al'Absi M. Hypothalamic-pituitary-adrenocortical responses to psychological stress and risk for smoking relapse. Int. J. Psychophysiol. 2006, 59:218-227.
3. al'Absi M., Wittmers L.E., Erickson J., Hatsukami D., Crouse B. Attenuated adrenocortical and blood pressure responses to psychological stress in ad libitum and abstinent smokers. Pharmacol. Biochem. Behav. 2003, 74:401-410.
4. al'Absi M., Hatsukami D., Davis G.L., Wittmers L.E. Prospective examination of effects of smoking abstinence on cortisol and withdrawal symptoms as predictors of early smoking relapse. Drug Alcohol. Depend. 2004, 73:267-278.
5. al'Absi M., Wittmers L.E., Ellestad D., Nordehn G., Kim S.W., Kirschbaum C., Grant J.E. Sex differences in pain and hypothalamic-pituitary-adrenocortical responses to opioid blockade. Psychosom. Med. 2004, 66:198-206.
6. al'Absi M., Hatsukami D., Davis G.L. Attenuated adrenocorticotropic responses to psychological stress are associated with early smoking relapse. Psychopharmacology (Berl.) 2005, 181:107-117.
7. al'Absi M., Wittmers L.E., Hatsukami D., Westra R. Blunted opiate modulation of hypothalamic-pituitary-adrenocortical activity in men and women who smoke. Psychosom. Med. 2008, 70:928-935.
8. Baron J.A., Comi R.J., Cryns V., Brinck-Johnsen T., Mercer N.G. The effect of cigarette smoking on adrenal cortical hormones. J. Pharmacol. Exp. Ther. 1995, 272:151-155.
9. Bart G., LaForge K.S., Borg L., Lilly C., Ho A., Kreek M.J. Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. Neuropsychopharmacology. 2006, 31:2313-2317.
10. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Arch. Gen. Psychiatry 1961, 4:561-571.
11. Berrendero F., Kieffer B.L., Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J. Neurosci. 2002, 22:10935-10940.
12. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., Maldonado R. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J. Neurosci. 2005, 25:1103-1112.
13. Born J., Ditschuneit I., Schreiber M., Dodt C., Fehm H.L. Effects of age and gender on pituitary-adrenocortical responsiveness in humans. Eur. J. Endocrinol. 1995, 132:705-711.
14. Brown D.R., Goldberg L.I. The use of quaternary narcotic antagonists in opiate research. Neuropharmacology 1985, 24:181-191.
15. Childs E., de Wit H. Hormonal, cardiovascular, and subjective responses to acute stress in smokers. Psychopharmacology (Berl.) 2009, 203:1-12.
16. Cohen M.R., Cohen R.M., Pickar D., Weingartner H., Murphy D.L. High-dose naloxone infusions in normals. Dose-dependent behavioral, hormonal, and physiological responses. Arch. Gen. Psychiatry 1983, 40:613-619.
17. Conaglen J.V., Donald R.A., Espiner E.A., Livesey J.H., Nicholls M.G. Effect of naloxone on the hormone response to CRF in normal man. Endocr. Res. 1985, 11:39-44.
18. Covey L.S., Glassman A.H., Stetner F. Naltrexone effects on short-term and long-term smoking cessation. J. Addict. Dis. 1999, 18:31-40.
19. Cryer P.E., Haymond M.W., Santiago J.V., Shah S.D. Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events. N. Engl. J. Med. 1976, 295:573-577.
20. Cushman P., Kreek M.J. Methadone-maintained patients. Effect of methadone on plasma testosterone, FSH, LH, and prolactin. N. Y. State J. Med. 1974, 74:1970-1973.
21. David S., Lancaster T., Stead L.F., Evins A.E. Opioid antagonists for smoking cessation. Cochrane Database Syst. Rev. 2006, CD003086.
22. Delitala G., Trainer P.J., Oliva O., Fanciulli G., Grossman A.B. Opioid peptide and alpha-adrenoceptor pathways in the regulation of the pituitary-adrenal axis in man. J. Endocrinol. 1994, 141:163-168.
23. Derogatis, L., 1983. SCL-90-R manual II. Towson (MD): Clinical Psychometric Research.
24. Dhillo W.S., Kong W.M., Le Roux C.W., Alaghband-Zadeh J., Jones J., Carter G., Mendoza N., Meeran K., O'Shea D. Cortisol-binding globulin is important in the interpretation of dynamic tests of the hypothalamic-pituitary-adrenal axis. Eur. J. Endocrinol. 2002, 146:231-235.
25. Epstein A.M., King A.C. Naltrexone attenuates acute cigarette smoking behavior. Pharmacol. Biochem. Behav. 2004, 77:29-37.
26. Farren C.K., O'Malley S., Grebski G., Maniar S., Porter M., Kreek M.J. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study. Alcohol Clin. Exp. Res. 1999, 23:502-508.
27. Fillingim R.B., Gear R.W. Sex differences in opioid analgesia: clinical and experimental findings. Eur. J. Pain 2004, 8:413-425.
28. First, M.B., Spitzer, R.L., Gibbon, M., Williams, J.B.W., 1995. Structured Clinical Interview for DSM-IV Axis I Disorders. Biometrics Research Department-patient edition (SCID-I/P, Version 2.0), New York, NY.
29. Fu Y., Matta S.G., Brower V.G., Sharp B.M. Norepinephrine secretion in the hypothalamic paraventricular nucleus of rats during unlimited access to self-administered nicotine: an in vivo microdialysis study. J. Neurosci. 2001, 21:8979-8989.
30. Gallucci W.T., Baum A., Laue L., Rabin D.S., Chrousos G.P., Gold P.W., Kling M.A. Sex differences in sensitivity of the hypothalamic-pituitary-adrenal axis. Health Psychol. 1993, 12:420-425.
31. Gear R.W., Gordon N.C., Heller P.H., Paul S., Miaskowski C., Levine J.D. Gender difference in analgesic response to the kappa-opioid pentazocine. Neurosci. Lett. 1996, 205:207-209.
32. Gear R.W., Miaskowski C., Gordon N.C., Paul S.M., Heller P.H., Levine J.D. Kappa-opioids produce significantly greater analgesia in women than in men. Nat. Med. 1996, 2:1248-1250.
33. Gear R.W., Miaskowski C., Gordon N.C., Paul S.M., Heller P.H., Levine J.D. The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 1999, 83:339-345.
34. Gear R.W., Gordon N.C., Miaskowski C., Paul S.M., Heller P.H., Levine J.D. Sexual dimorphism in very low dose nalbuphine postoperative analgesia. Neurosci. Lett. 2003, 339:1-4.
35. Hammer R.P., Bridges R.S. Preoptic area opioids and opiate receptors increase during pregnancy and decrease during lactation. Brain Res. 1987, 420:48-56.
36. Hammer R.P., Bogic L., Handa R.J. Estrogenic regulation of proenkephalin mRNA expression in the ventromedial hypothalamus of the adult male rat. Brain Res. Mol. Brain. Res. 1993, 19:129-134.
37. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br. J. Addict. 1991, 86:1119-1127.
38. Heuser I.J., Gotthardt U., Schweiger U., Schmider J., Lammers C.H., Dettling M., Holsboer F. Age-associated changes of pituitary-adrenocortical hormone regulation in humans: importance of gender. Neurobiol. Aging 1994, 15:227-231.
39. Hill P., Wynder E.L. Smoking and cardiovascular disease. Effect of nicotine on the serum epinephrine and corticoids. Am. Heart J. 1974, 87:491-496.
40. Hughes J.R., Keely J., Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 2004, 99:29-38.
41. Huston-Lyons D., Sarkar M., Kornetsky C. Nicotine and brain-stimulation reward: interactions with morphine, amphetamine and pimozide. Pharmacol. Biochem. Behav. 1993, 46:453-457.
42. Hutchison K.E., Monti P.M., Rohsenow D.J., Swift R.M., Colby S.M., Gnys M., Niaura R.S., Sirota A.D. Effects of naltrexone with nicotine replacement on smoking cue reactivity: preliminary results. Psychopharmacology (Berl.) 1999, 142:139-143.
43. Hynes M.D., Gianutsos G., Lal H. Effects of cholinergic agonists and antagonists on morphine-withdrawal syndrome. Psychopharmacology (Berl.) 1976, 49:191-195.
44. Johnson E.O., Kamilaris T.C., Chrousos G.P., Gold P.W. Mechanisms of stress: a dynamic overview of hormonal and behavioral homeostasis. Neurosci. Biobehav. Rev. 1992, 16:115-130.
45. King A.C., Meyer P.J. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol. Biochem. Behav. 2000, 66:563-572.
46. King A.C., Schluger J., Gunduz M., Borg L., Perret G., Ho A., Kreek M.J. Hypothalamic-pituitary-adrenocortical (HPA) axis response and biotransformation of oral naltrexone: preliminary examination of relationship to family history of alcoholism. Neuropsychopharmacology 2002, 26:778-788.
47. King A., de Wit H., Riley R.C., Cao D., Niaura R., Hatsukami D. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob. Res. 2006, 8:671-682.
48. King A.C., Torello R., Krishnan-Sarin S., O'Malley S.S. Naltrexone in smoking cessation: a review of the literature and future directions. Opioid Receptors and Antagonists: from Bench to Clinic 2009, 307-324. Humana Press, Totowa, NJ. R. Dean, E. Bilsky, S. Negus (Eds.).
49. Kirschbaum C., Wust S., Strasburger C.J. 'Normal' cigarette smoking increases free cortisol in habitual smokers. Life Sci. 1992, 50:435-442.
50. Kirschbaum C., Strasburger C.J., Langkrar J. Attenuated cortisol response to psychological stress but not to CRH or ergometry in young habitual smokers. Pharmacol. Biochem. Behav. 1993, 44:527-531.
51. Kirschbaum C., Scherer G., Strasburger C.J. Pituitary and adrenal hormone responses to pharmacological, physical, and psychological stimulation in habitual smokers and nonsmokers. Clin. Investig. 1994, 72:804-810.
52. Kirschbaum C., Pirke K.M., Hellhammer D.H. Preliminary evidence for reduced cortisol responsivity to psychological stress in women using oral contraceptive medication. Psychoneuroendocrinology 1995, 20:509-514.
53. Kirschbaum C., Klauer T., Filipp S.H., Hellhammer D.H. Sex-specific effects of social support on cortisol and subjective responses to acute psychological stress. Psychosom. Med. 1995, 57:23-31.
54. Kirschbaum C., Kudielka B.M., Gaab J., Schommer N.C., Hellhammer D.H. Impact of gender, menstrual cycle phase, and oral contraceptives on the activity of the hypothalamus-pituitary-adrenal axis. Psychosom. Med. 1999, 61:154-162.
55. Klein L.C., Jamner L.D., Alberts J., Orenstein M.D., Levine L., Leigh H. Sex differences in salivary cortisol levels following naltrexone administration. J Appl. Biobehav. Res. 2000, 5:144-153.
56. Kosten T.R., Kreek M.J., Ragunath J., Kleber H.D. Chronic naltrexone effect on cortisol. NIDA Res. Monogr. 1986, 67:362-365.
57. Kosten T.R., Kreek M.J., Ragunath J., Kleber H.D. Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts. Biol. Psychiatry 1986, 21:217-220.
58. Kosten T.R., Kreek M.J., Ragunath J., Kleber H.D. A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts. Life Sci. 1986, 39:55-59.
59. Kreek M.J. Physiologic implications of methadone treatment. Proc. Natl. Conf. Methadone Treat. 1973, 2:824-838.
60. Kreek M.J. Medical complications in methadone patients. Ann. N. Y. Acad. Sci. 1978, 311:110-134.
61. Kreek M.J., Dodes L., Kane S., Knobler J., Martin R. Long-term methadone maintenance therapy: effects on liver function. Ann. Intern. Med. 1972, 77:598-602.
62. Kreek M.J., Ragunath J., Plevy S., Hamer D., Schneider B., Hartman N. ACTH, cortisol and beta-endorphin response to metyrapone testing during chronic methadone maintenance treatment in humans. Neuropeptides 1984, 5:277-278.
63. Krishnan-Sarin S., Rosen M.I., O'Malley S.S. Naloxone challenge in smokers. Preliminary evidence of an opioid component in nicotine dependence. Arch. Gen. Psychiatry 1999, 56:663-668.
64. Kudielka B.M., Hellhammer J., Hellhammer D.H., Wolf O.T., Pirke K.M., Varadi E., Pilz J., Kirschbaum C. Sex differences in endocrine and psychological responses to psychosocial stress in healthy elderly subjects and the impact of a 2-week dehydroepiandrosterone treatment. J. Clin. Endocrinol. Metab. 1998, 83:1756-1761.
65. Kudielka B.M., Buske-Kirschbaum A., Hellhammer D.H., Kirschbaum C. HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology. 2004, 29:83-98.
66. Kudielka B.M., Hellhammer D.H., Wust S. Why do we respond so differently? Reviewing determinants of human salivary cortisol responses to challenge. Psychoneuroendocrinology 2009, 34:2-18.
67. Kumsta R., Entringer S., Koper J.W., van Rossum E.F., Hellhammer D.H., Wust S. Sex specific associations between common glucocorticoid receptor gene variants and hypothalamus-pituitary-adrenal axis responses to psychosocial stress. Biol. Psychiatry 2007, 62:863-869.
68. Kunzel H.E., Binder E.B., Nickel T., Ising M., Fuchs B., Majer M., Pfennig A., Ernst G., Kern N., Schmid D.A., Uhr M., Holsboer F., Modell S. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test. Neuropsychopharmacology 2003, 28:2169-2178.
69. LeResche L., Mancl L., Sherman J.J., Gandara B., Dworkin S.F. Changes in temporomandibular pain and other symptoms across the menstrual cycle. Pain 2003, 106:253-261.
70. Malin D.H., Lake J.R., Carter V.A., Cunningham J.S., Wilson O.B. Naloxone precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl.) 1993, 112:339-342.
71. Malin D.H., Lake J.R., Payne M.C., Short P.E., Carter V.A., Cunningham J.S., Wilson O.B. Nicotine alleviation of nicotine abstinence syndrome is naloxone-reversible. Pharmacol. Biochem. Behav. 1996, 53:81-85.
72. Malin D.H., Lake J.R., Short P.E., Blossman J.B., Lawless B.A., Schopen C.K., Sailer E.E., Burgess K., Wilson O.B. Nicotine abstinence syndrome precipitated by an analog of neuropeptide FF. Pharmacol. Biochem. Behav. 1996, 54:581-585.
73. Martin del Campo A.F., Dowson J.H., Herbert J., Paykel E.S. Effects of naloxone on diurnal rhythms in mood and endocrine function: a dose-response study in man. Psychopharmacology (Berl.) 1994, 114:583-590.
74. Matta S.G., Fu Y., Valentine J.D., Sharp B.M. Response of the hypothalamo-pituitary-adrenal axis to nicotine. Psychoneuroendocrinology 1998, 23:103-113.
75. Meliska C.J., Gilbert D.G. Hormonal and subjective effects of smoking the first five cigarettes of the day: a comparison in males and females. Pharmacol. Biochem. Behav. 1991, 40:229-235.
76. Mendelson J.H., Sholar M.B., Goletiani N., Siegel A.J., Mello N.K. Effects of low- and high-nicotine cigarette smoking on mood states and the HPA axis in men. Neuropsychopharmacology 2005, 30:1751-1763.
77. Mendelson J.H., Goletiani N., Sholar M.B., Siegel A.J., Mello N.K. Effects of smoking successive low- and high-nicotine cigarettes on hypothalamic-pituitary-adrenal axis hormones and mood in men. Neuropsychopharmacology 2008, 33:749-760.
78. Mogil J.S., Wilson S.G., Chesler E.J., Rankin A.L., Nemmani K.V., Lariviere W.R., Groce M.K., Wallace M.R., Kaplan L., Staud R., Ness T.J., Glover T.L., Stankova M., Mayorov A., Hruby V.J., Grisel J.E., Fillingim R.B. The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:4867-4872.
79. Morley J.E., Baranetsky N.G., Wingert T.D., Carlson H.E., Hershman J.M., Melmed S., Levin S.R., Jamison K.R., Weitzman R., Chang R.J., Varner A.A. Endocrine effects of naloxone-induced opiate receptor blockade. J. Clin. Endocrinol. Metab. 1980, 50:251-257.
80. Naber D., Pickar D., Davis G.C., Cohen R.M., Jimerson D.C., Elchisak M.A., Defraites E.G., Kalin N.H., Risch S.C., Buchsbaum M.S. Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone. HVA and MHPG in plasma of normal volunteers. Psychopharmacology (Berl.) 1981, 74:125-128.
81. Narkiewicz K., van de Borne P.J., Hausberg M., Cooley R.L., Winniford M.D., Davison D.E., Somers V.K. Cigarette smoking increases sympathetic outflow in humans. Circulation 1998, 98:528-534.
82. O'Malley S.S., Cooney J.L., Krishnan-Sarin S., Dubin J.A., McKee S.A., Cooney N.L., Blakeslee A., Meandzija B., Romano-Dahlgard D., Wu R., Makuch R., Jatlow P. A controlled trial of naltrexone augmentation of nicotine replacement therapy for smoking cessation. Arch. Intern. Med. 2006, 166:667-674.
83. Perkins K.A., Grobe J.E., Fonte C., Breus M. Paradoxical effects of smoking on subjective stress versus cardiovascular arousal in males and females. Pharmacol. Biochem. Behav. 1992, 42:301-311.
84. Pomerleau O.F., Pomerleau C.S. Cortisol response to a psychological stressor and/or nicotine. Pharmacol. Biochem. Behav. 1990, 36:211-213.
85. Pomerleau O.F., Fertig J.B., Seyler L.E., Jaffe J. Neuroendocrine reactivity to nicotine in smokers. Psychopharmacology (Berl.) 1983, 81:61-67.
86. Quinones-Jenab V., Jenab S., Ogawa S., Inturrisi C., Pfaff D.W. Estrogen regulation of mu-opioid receptor mRNA in the forebrain of female rats. Brain Res. Mol. Brain Res. 1997, 47:134-138.
87. Ray R., Jepson C., Patterson F., Strasser A., Rukstalis M., Perkins K., Lynch K.G., O'Malley S., Berrettini W.H., Lerman C. Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl.) 2006, 188:355-363.
88. Rohleder N., Kirschbaum C. The hypothalamic-pituitary-adrenal (HPA) axis in habitual smokers. Int. J. Psychophysiol. 2006, 59:236-243.
89. Sarton E., Olofsen E., Romberg R., den Hartigh J., Kest B., Nieuwenhuijs D., Burm A., Teppema L., Dahan A. Sex differences in morphine analgesia: an experimental study in healthy volunteers. Anesthesiology 2000, 93:1245-1254. discussion 1246A.
90. Schluger J.H., Ho A., Borg L., Porter M., Maniar S., Gunduz M., Perret G., King A., Kreek M.J. Nalmefene causes greater hypothalamic-pituitary-adrenal axis activation than naloxone in normal volunteers: implications for the treatment of alcoholism. Alcohol. Clin. Exp. Res. 1998, 22:1430-1436.
91. Schmidt B.L., Tambeli C.H., Gear R.W., Levine J.D. Nicotine withdrawal hyperalgesia and opioid-mediated analgesia depend on nicotine receptors in nucleus accumbens. Neuroscience 2001, 106:129-136.
92. Seeman T.E., Singer B., Wilkinson C.W., McEwen B. Gender differences in age-related changes in HPA axis reactivity. Psychoneuroendocrinology 2001, 26:225-240.
93. Selzer M.L., Vinokur A., van Rooijen L. A self-administered Short Michigan Alcoholism Screening Test (SMAST). J. Stud. Alcohol. 1975, 36:117-126.
94. Shaw D., al'Absi M. Attenuated beta endorphin response to acute stress is associated with smoking relapse. Pharmacol. Biochem. Behav. 2008, 90:357-362.
95. Smith Y.R., Zubieta J.K., del Carmen M.G., Dannals R.F., Ravert H.T., Zacur H.A., Frost J.J. Brain opioid receptor measurements by positron emission tomography in normal cycling women: relationship to luteinizing hormone pulsatility and gonadal steroid hormones. J. Clin. Endocrinol. Metab. 1998, 83:4498-4505.
96. Smith Y.R., Stohler C.S., Nichols T.E., Bueller J.A., Koeppe R.A., Zubieta J.K. Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women. J. Neurosci. 2006, 26:5777-5785.
97. Spielberger, C.D., Edwards, C.D., Mantoun, J., Lushene, R.E., 1987. The State -Trait Inventory. Windsor: NFER-Nelson.
98. Sutherland G., Stapleton J.A., Russell M.A., Feyerabend C. Naltrexone, smoking behaviour and cigarette withdrawal. Psychopharmacology (Berl.) 1995, 120:418-425.
99. Tsuda A., Steptoe A., West R., Fieldman G., Kirschbaum C. Cigarette smoking and psychophysiological stress responsiveness: effects of recent smoking and temporary abstinence. Psychopharmacology (Berl.) 1996, 126:226-233.
100. Uhart M., Chong R.Y., Oswald L., Lin P.I., Wand G.S. Gender differences in hypothalamic-pituitary-adrenal (HPA) axis reactivity. Psychoneuroendocrinology 2006, 31:642-652.
101. Ukai M., Holtzman S.G. Suppression of deprivation-induced water intake in the rat by opioid antagonists: central sites of action. Psychopharmacology (Berl.) 1987, 91:279-284.
102. Valentino R.J., Van Bockstaele E. Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Potential for reciprocal interactions between stress and opioid sensitivity. Psychopharmacology (Berl.) 2001, 158:331-342.
103. Volavka J., Cho D., Mallya A., Bauman J. Naloxone increases ACTH and cortisol levels in man. N. Engl. J. Med. 1979, 300:1056-1057.
104. Wiegratz I., Kutschera E., Lee J.H., Moore C., Mellinger U., Winkler U.H., Kuhl H. Effect of four oral contraceptives on thyroid hormones, adrenal and blood pressure parameters. Contraception 2003, 67:361-366.
105. Wiegratz I., Kutschera E., Lee J.H., Moore C., Mellinger U., Winkler U.H., Kuhl H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003, 67:25-32.
106. Wilkins J.N., Carlson H.E., Van Vunakis H., Hill M.A., Gritz E., Jarvik M.E. Nicotine from cigarette smoking increases circulating levels of cortisol, growth hormone, and prolactin in male chronic smokers. Psychopharmacology (Berl.) 1982, 78:305-308.
107. Winternitz W.W., Quillen D. Acute hormonal response to cigarette smoking. J. Clin. Pharmacol. 1977, 17:389-397.
108. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., Hurt R.D. A randomized trial of naltrexone for smoking cessation. Addiction 1999, 94:1227-1237.
109. Zacny J.P. Morphine responses in humans: a retrospective analysis of sex differences. Drug Alcohol. Depend. 2001, 63:23-28.
110. Zarrindast M.R., Faraji N., Rostami P., Sahraei H., Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol. Biochem. Behav. 2003, 74:363-369.
111. Zhou L., Hammer R.P. Gonadal steroid hormones upregulate medial preoptic mu-opioid receptors in the rat. Eur. J. Pharmacol. 1995, 278:271-274.
112. Zubieta J.K., Dannals R.F., Frost J.J. Gender and age influences on human brain mu-opioid receptor binding measured by PET. Am. J. Psychiatry. 1999, 156:842-848.
113. Zubieta J.K., Smith Y.R., Bueller J.A., Xu Y., Kilbourn M.R., Jewett D.M., Meyer C.R., Koeppe R.A., Stohler C.S. Mu-opioid receptor-mediated antinociceptive responses differ in men and women. J. Neurosci. 2002, 22:5100-5107.